Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia

PHASE3TerminatedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Dementia, VascularDementia, Mixed
Interventions
DRUG

Donepezil

donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks

Trial Locations (30)

T5C 0A3

Pfizer Investigational Site, Belvedere

T5A 4L8

Pfizer Investigational Site, Edmonton

T6A 0A5

Pfizer Investigational Site, Edmonton

V2S 3P8

Pfizer Investigational Site, Abbotsford

V3K 3P4

Pfizer Investigational Site, Coquitlam

V8T 5G1

Pfizer Investigational Site, Victoria

R2H 0R8

Pfizer Investigational Site, Winnipeg

E2L 3L6

Pfizer Investigational Site, Saint John

B4H 4R7

Pfizer Investigational Site, Amherst

B3H 2E1

Pfizer Investigational Site, Halifax

B0K 1H0

Pfizer Investigational Site, Pictou

L7M 4Y1

Pfizer Investigational Site, Burlington

N0N 1G0

Pfizer Investigational Site, Corunna

L2A 1Z3

Pfizer Investigational Site, Fort Erie

K6A 1A1

Pfizer Investigational Site, Hawkesbury

P1B 2H3

Pfizer Investigational Site, North Bay

K1N 5C8

Pfizer Investigational Site, Ottawa

K2C 3R2

Pfizer Investigational Site, Ottawa

K2G 3Y5

Pfizer Investigational Site, Ottawa

K9H 2P4

Pfizer Investigational Site, Peterborough

N7T 4X3

Pfizer Investigational Site, Sarnia

M3B 2W7

Pfizer Investigational Site, Toronto

G1J 2G3

Pfizer Investigational Site, Beauport

J2K 2X9

Pfizer Investigational Site, Cowansville

G2E 2X1

Pfizer Investigational Site, L'Ancienne-Lorette

H1T 2M4

Pfizer Investigational Site, Montreal

G5L 9A8

Pfizer Investigational Site, Rimouski

J2W 2A3

Pfizer Investigational Site, Saint-Jean-sur-Richelieu

H1S 3A9

Pfizer Investigational Site, Saint-Léonard

S4P 3X1

Pfizer Investigational Site, Regina

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY